|The BID bid (Catalog #MBS221364) is an Antibody produced from Goat and is intended for research purposes only. The product is available for immediate purchase. MyBioSource\'s BID can be used in a range of immunoassay formats including, but not limited to, ELISA (EIA), Western Blot (WB).
Western Blot: This item detects bands of approximately 26kDa and 24kDa in A431 cell lysates.
ELISA: Maximum Dilution: 1/8000
Western Blotting: Minimum Dilution: 0.1; Maximum Dilution: 0.3ug/ml. Researchers should empirically determine the suitability of the BID bid for an application not listed in the data sheet. Researchers commonly develop new applications and it is an integral, important part of the investigative research process.
The BID bid product has the following accession number(s) (GI #4557361) (NCBI Accession #NP_001187.1) (Uniprot Accession #P55957). Researchers may be interested in using Bioinformatics databases such as those available at The National Center for Biotechnology Information (NCBI) website for more information about accession numbers and the proteins they represent. Even researchers unfamiliar with bioinformatics databases will find the NCBI databases to be quite user friendly and useful.
To buy or view more detailed product information and pricing, please click on the technical datasheet page below:
MBS221364 detects an epitope within the C-terminus of BID, a death agonist that heterodimerizes with other members of the Bcl-2 family of cell death regulators; including the agonist BAX or antagonist BCL2. BID contains a BH3 domain, which is required for its interaction with the Bcl-2 family proteins and for its pro-death activity. BID is susceptible to proteolytic cleavage by caspases, calpains, Granzyme B and cathepsins. Protease-cleaved BID translocates to mitochondria where it results in cytochrome c release, leading to caspase activation and cell death. This constitutes the activation of the mitochondria death pathway (the intrinsic pathway) by the death stimuli. BID has been shown to promote cell cycle progression into S phase, whilst BID could be also involved in the maintenance of genomic stability by engaging at mitosis checkpoint. Deletion of BID inhibits carcinogenesis in the liver, and promotes tumorigenesis in the myeloid cells.
Perservative Stabilisers: 0.02% Sodium Azide (NaN3)
0.5% Bovine Serum Albumin. Immunogen: Peptide with sequence C-TYVRSLARNGMD from the C-terminus of BID
Buffer Solution: TRIS buffered saline
Antiserum Preparation: Antisera to BID (CT) were raised by repeated immunisations of goat with highly purified antigen. Purified IgG prepared affinity chromatography.
Target Species: Human. In general, we may offer more than one antibody to a given target to enable options for the researcher. Available antibodies recognizing BID are readily searchable from our website. Different antibodies against the same target such as BID may be optimized or tested for different applications and species. This enables researchers to select the option that may be best for their model system, to screen more than antibody to determine which one may be best for their model system, as well as to use more than one antibody to follow up on and validate their results. Adenocarcinoma, Cardiovascular Diseases, Diarrhea, Gastrointestinal Diseases, Heart Diseases, Hypertension, Lung Diseases, Necrosis, Nervous System Diseases, Pain are some of the diseases may be linked to GOAT ANTI HUMAN BID (C-TERMINAL).